Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chongqing Precision Biotech Co: Clinical Trials & FDA Approval Profile

Chongqing Precision Biotech Co (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (4 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)11 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chongqing Precision Biotech Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)4 (4)
Completed vs Stopped Early2 / 1 (6.3%)
Median Closed Actual Enrollment11 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chongqing Precision Biotech Co
Hospital Research SiteLocationShared Protocols
Chongqing University Cancer HospitalChongqing5
Shanxi Bethune HospitalTaiyuan2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chongqing Precision Biotech Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05334823A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Chongqing Precision Biotech Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI